Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primates

12 May 2025

Abstract excerpt

BACKGROUND: Angiopoietin-like protein 4 (ANGPTL4) inhibition is a promising approach to manage atherogenic dyslipidaemia and residual atherosclerotic cardiovascular disease (ASCVD) risk. Human ANGPTL4 loss-of-function (LoF) is associated with reduced plasma triglyceride (TG), remnant cholesterol (RC), and apolipoprotein B (ApoB) levels, and lower risk of type 2 diabetes and ASCVD, without observable safety...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis and VEGF in Cancer
Share to Diabetes, Cardiovascular Risks, and Lipoproteins
Share to Lipid metabolism and disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40360349
DOI: 10.1016/j.ebiom.2025.105748

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primatesPMID 40360349Read ↗

A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in miceSemantic proximity Read ↗

Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice.Semantic proximity Read ↗

ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases.Semantic proximity Read ↗

Selective Targeting of Angiopoietin-like 3 (ANGPTL3) with Vupanorsen for the Treatment of Patients with Familial Partial Lipodystrophy (FPLD): Results of a Proof-of-Concept StudySemantic proximity Read ↗

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.Semantic proximity Read ↗

Dual Control of LDL-cholesterol Levels by ANGPTL3 and ANGPTL8Semantic proximity Read ↗

Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease.Semantic proximity Read ↗

Structures of Angptl3 and Angptl4, modulators of triglyceride levels and coronary artery diseaseSemantic proximity Read ↗

Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysisSemantic proximity Read ↗

Adipose Factor ANGPTL4: Its Role in Aging Mechanisms and Associated DiseasesSemantic proximity Read ↗

Genetic inhibition of angiopoietin-like protein-3, lipoprotein-lipid levels and cardiometabolic diseasesSemantic proximity Read ↗

Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic riskSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.